JNJ's REMICADE Holds: PFE's Results To Confirm
Johnson & Johnson (JNJ US) reported Q2 2017 results today (quotes from earnings call are below). US revenue for REMICADE (reference product for...
513 Views
Olympus--Dead Money for Momentum Investors; Dip-Buying Time for Long-Term Investors
Olympus generates 98% of its profits from endoscopes sales and has a 70% global share of gastro enteral endoscope systems. Their current line-up is...
265 Views
Actelion / Johnson & Johnson: Tendered Vs Untendered Lines
Any deal-threatening risks to the Actelion / Johnson & Johnson transaction were assuaged in late March and we now solely await EC antitrust...
359 Views
The Week That Was in NorthAsia@Smartkarma - THAAD Deployment, Mobile Lineage, and Activism in Japan
KoreaScott Laprise/ 乐天虎 and Prasenjit K. Basu have provided great insights regarding the political turmoil surrounding North Korea. Scott makes it...
239 Views
The Disconnect Is Growing
Celltrion Inc (068270 KS) 's Inflectra, a biosimilar to Johnson & Johnson (JNJ US) 's Remicade, had little impact on the critical U.S. market...
607 Views